RankAlpha logo
Back to Rankings

SLN

Silence TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The bull case is that divesiran is the primary asset the market cares about and the company has already de-risked execution somewhat by finishing SANRECO enrollment ahead of schedule, with 3Q 2026 topline data now the key unlock [#PR-2025-10-23][#PR-2026-03-05].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.1.
What can break
AstraZeneca notified Silence on March 4, 2026 that it will not pursue further SLN312 development beyond Phase 1, reducing one external validation path.
Momentum
98
Value
41
Sentiment
9
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $11.00 · Bear $3.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $31.20
Why
Momentum98 · Δ7d +0.1
Value41 · Δ7d +0.1
Sentiment9 · Δ7d -9.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
98
26% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+6.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
9
34% active weight
Current posture
7d trendSoftening
Δ7d
-9.2
Δ21d
-0.9
Why this grade

Composite grade D. Momentum 97.7 / Value 41.1 / Sentiment 9.5

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$495.49M
Beta
0.56
Shares Out
47.23M
P/E (TTM) · Derived
-5.6
P/S (TTM)
10.85
P/FCF (TTM)
6.91
Rev YoY
+195.6%
EPS YoY
-47.9%
Gross Margin
+28.2%
Op Margin
-326.4%
Net Debt
-$84.95M
Current Ratio
9.83
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology